Literature DB >> 6414432

Inhibitory action of virginiamycin components on cell-free systems for polypeptide formation from Bacillus subtilis.

C Cocito, F Vanlinden.   

Abstract

Although virginiamycin components VM and VS are known to exert in vivo a synergistic inhibition of bacterial growth and viability, in cell-free systems only VM has proven active. In the present work, the in vivo and in vitro activities of VM and VS on Bacillus subtilis have been compared. Peptide formation in homogenates of bacteria previously incubated with either VM or VS was found strongly repressed; the 2 components acted synergistically. Ribosomes were fully responsible for this effect, as shown by mixed reconstitution experiments. On the other hand, cytoplasm from control bacteria disrupted in 10 mM Mg2+ buffer was refractory to in vitro inhibition by virginiamycin, whereas ribosomes prepared in 1 mM Mg2+ were sensitive to VM. VS was inactive on poly(U)-directed poly(phenylalanine) formation, and displayed some activity on the poly(A)-poly(lysine) system. In a cell-free system from Bacillus subtilis infected with phage 2C, both VM and VS were active and blocked synergistically protein synthesis in vitro. When the host cells were incubated with VS and the corresponding homogenate was then treated with VM, a complete inhibition of protein synthesis was observed. The present work, thus, describes the techniques for investigating the in vivo and in vitro action of synergimycins on the same organism, and for reproducing in vitro the synergistic interaction of type A and B components previously observed only in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414432     DOI: 10.1007/BF00419474

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  21 in total

1.  INHIBITION BY VERNAMYCIN A OF AMINO ACID INCORPORATION IN ESCHERICHIA COLI CELL-FREE SYSTEMS.

Authors:  A I LASKIN; W M CHAN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

Review 2.  Insights into protein biosynthesis and ribosome function through inhibitors.

Authors:  S Pestka
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1976

Review 3.  Inhibitors of protein synthesis.

Authors:  D Vazquez
Journal:  FEBS Lett       Date:  1974-03-23       Impact factor: 4.124

4.  Studies on transfer ribonucleic acid-ribosome complexes. XIX. Effect of antibiotics on peptidyl puromycin synthesis on polyribosoms from Escherichia coli.

Authors:  S Pestka
Journal:  J Biol Chem       Date:  1972-07-25       Impact factor: 5.157

5.  Virginiamycin M, a specific inhibitor of the acceptor site of ribosomes.

Authors:  C Cocito; A Kaji
Journal:  Biochimie       Date:  1971       Impact factor: 4.079

6.  The mechanism of action of virginiamycin M on the binding of aminoacyl-tRNA to ribosomes directed by elongation factor Tu.

Authors:  G Chinali; P Moureau; C G Cocito
Journal:  Eur J Biochem       Date:  1981-09-01

7.  The in vitro and in vivo inactivation of ribosomes by virginiamycin M does not entail an alteration of 5, 16 and 23 S ribosomal RNA.

Authors:  C Cocito; F Vanlinden; C Branlant
Journal:  Biochim Biophys Acta       Date:  1983-03-10

8.  Inhibition of protein synthesis by polypeptide antibiotics. I. Inhibition in intact bacteria.

Authors:  H L Ennis
Journal:  J Bacteriol       Date:  1965-10       Impact factor: 3.490

9.  Inhibition of protein synthesis by polypeptide antibiotics.. II. In vitro protein synthesis.

Authors:  H L Ennis
Journal:  J Bacteriol       Date:  1965-10       Impact factor: 3.490

10.  Competition between erythromycin and virginiamycin for in vitro binding to the large ribosomal subunit.

Authors:  R Parfait; M Di Giambattista; C Cocito
Journal:  Biochim Biophys Acta       Date:  1981-07-27
View more
  1 in total

1.  Synergy of streptogramin antibiotics occurs independently of their effects on translation.

Authors:  Jonas Noeske; Jian Huang; Nelson B Olivier; Robert A Giacobbe; Mark Zambrowski; Jamie H D Cate
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.